K. Walczyn´ski et al. / Il Farmaco 54 (1999) 684–694
693
potential of histamine H3-receptor agonists and antagonists,
TiPS 19 (1998) 177–183.
[14] J.-M. Arrang, M. Garbarg, J.-C. Schwartz, Auto-inhibition of
brain histamine release mediated by a novel class (H3) of his-
tamine receptor, Nature (London) 302 (1983) 832–837.
[15] E. Schlicker, R. Betz, M. Go¨thert, Histamine H3-receptor-medi-
ated inhibition of serotonin release in the rat brain cortex,
Naunyn-Schmideberg’s Arch. Pharmacol. 337 (1988) 588–590.
[16] E. Schlicker, K. Fink, M. Hinterthaner, M. Go¨thert, Inhibition
of noradrenaline release in the rat brain cortex via presynaptic
H3-receptors, Naunyn-Schmideberg’s Arch. Pharmacol. 340
(1989) 633–638.
[17] J. Clapham, G.J. Kilpatrick, Histamine H3-receptors modulate
the release of [3H]-acetylcholine from slices of rat entorhinal
cortex-evidence for the possible existence of H3-receptor sub-
types, Br. J. Pharmacol. 107 (1992) 919–923.
[18] E. Schlicker, M. Malinowska, M. Kathmann, M. Go¨thert, Mod-
ulation of neurotransmitter release via histamine H3-heterorecep-
tors, Fundam. Clin. Pharmacol. 8 (1994) 128–137.
[34] H. Stark, E. Schlicker, W. Schunack, Developments of histamine
H3-receptor antagonists, Drugs Future 21 (1996) 507–520.
[35] H. Stark, M. Krause, J.-M. Arrang, X. Ligneau, J.-C. Schwartz,
W. Schunack, Unsymmetrically substituted guanidines as potent
histamine H3-receptor antagonists, Bioorg. Med. Chem. Lett. 4
(1994) 2907–2912.
[36] H. Stark, K. Purand, X. Ligneau, A. Rouleau, J.-M. Arrang, M.
Garbarg, J.-C. Schwartz, W. Schunack, Novel carbamates as
potent histamine H3-receptor antagonists with high in vitro and
oral in vivo activity, J. Med. Chem. 39 (1996) 1157–1163.
[37] A. Hu¨ls, K. Purand, H. Stark, S. Reidemeister, X. Ligneau,
J.-M. Arrang, J.-C. Schwartz, W. Schunack, Novel histamine
H3-receptor antagonists with benzyl ether structure or related
moieties: synthesis and structure–activity relationships, Arch.
Pharm. 329 (1996) 379–385.
[38] C.R. Ganellin, S.K. Hosseini, Y.S Khalaf, W. Tertiuk, J.-M.
Arrang, M. Garbarg, X. Ligneau, J.-C. Schwartz, Design of
potent non-thiourea H3-receptor antagonists, J. Med. Chem. 38
(1995) 3342–3350.
[19] M. Ichinose, P.J. Barnes, Histamine H3-receptors modulate non-
adrenergic noncholinergic neural bronchoconstriction in guinea
pig in vivo, Eur. J. Pharmacol. 174 (1989) 49–55.
[20] G.J. Menkveld, H. Timmerman, Inhibition of electrically evoked
contractions of guinea pig ileum preparations mediated by the
histamine H3-receptor, Eur. J. Pharmacol. 186 (1990) 343–347.
[21] G. Coruzzi, E. Poli, G. Bertaccini, Histamine receptors in iso-
lated guinea pig duodenal muscle: H3-receptors inhibit choliner-
gic neurotransmission, J. Pharmacol. Exp. Ther. 258 (1991)
325–331.
[22] R.C. Vollinga, O.P. Zuiderveld, H. Scheerens, A. Bast, H.
Timmerman, Simple and rapid in vitro test system for the
screening of histamine H3 ligands, Meth. Find. Exp. Clin. Phar-
macol. 105 (1992) 747–751.
[23] S.J. Taylor, G.J. Kilpatrick, Characterization of histamine H3-
receptors controlling non-adrenergic non-cholinergic contrac-
tions of the guinea pig isolated ileum, Br. J. Pharmacol. 105
(1992) 667–670.
[24] J.P. Trzeciakowski, Inhibition of guinea pig ileum contractions
mediated by a class of receptor resembling the H3 subtype, J.
Pharmacol. Exp. Ther. 243 (1987) 874–880.
[25] S. Ishikawa, N. Sperelakis, A novel class (H3) of histamine
receptors on perivascular nerve terminals, Nature (London) 327
(1987) 158–160.
[26] L. Ea-Kim, N. Oudart, A highly potent and selective H3-agonist
relaxes rabbit middle cerebral artery, Eur. J. Pharmacol. 150
(1988) 393–396.
[27] M. Ichinose, C.D. Stretton, J.-C. Schwartz, P.J. Barnes, His-
tamine H3-receptors inhibit cholinergic neurotransmission in
guinea-pig airways, Br. J. Pharmacol. 97 (1989) 13–15.
[28] I.Z. Andjelkovic, C.S. Collis, M.A. Rosic, M.B. Segal, B.Z.
Zlokovic, Effects of N-alphamethylhistamine on the isolated
guinea-pig heart, J. Physiol. 424 (1990) 58P.
[29] J.-M. Arrang, M. Garbarg, J.M. Lancelot, J.M. Lecome, H.
Pollard, M. Robba, W. Schunack, J.-C. Schwartz, Highly potent
and selective ligands for histamine H3-receptors, Nature (Lon-
don) 327 (1987) 117–123.
[39] J.W. Clitherow, P. Beswick, W.J. Irving, D.J.C. Scopes, J.C.
Barnes, J. Clapham, J.D. Brown, D.J. Evans, A.G. Hayes, Novel
1,2,4-oxadiazoles as potent and selective histamine H3-receptor
antagonists, Bioorg. Med. Chem. Lett. 6 (1996) 833–838.
[40] J.G. Philips, T.E. Clarck, Chaturvedi Nishith, Preparation of
1H-4(5)-substituted imidazole derivatives as histamine H3-recep-
tor antagonists, USA Patent Appl. (PCT) WO 9638, 142 (1996)
[Chem. Abstr. 126, 118194q (1997)].
[41] S.M. Ali, C.E Tedford, R. Gregory, S.L. Yates, J.G. Philips,
New acetylene based histamine H3-receptor antagonists derived
from the marine natural product verongamine, Bioorg. Med.
Chem. Lett. 8 (1998) 1133–1138.
[42] H. Van der Goot, M.J.P. Schepers, G.J. Sterk, H. Timmerman,
Isothiourea analogues of histamine as potent agonists or antago-
nists of the histamine H3-receptor, Eur. J. Med. Chem. 27 (1992)
511–517.
[43] J.-M. Arrang, M. Garbarg, T.T. Quach, M.D. Trung Tuong, E.
Yeramian, J.-C. Schwartz, Action of betahistine at histamine
H3-receptors in the brain, Eur. J. Pharmacol. 111 (1985) 73–84.
[44] J.-M. Arrang, N. Defontaine, J.-C. Schwartz, Phencyclidine
blocks histamine H3-receptors in the brain, Eur. J. Pharmacol.
157 (1988) 31–35.
[45] J.-C. Schwartz, J.-M. Arrang, M. Garbarg, H.A. Pollard, The
histamine receptor subtype: characterisation, localisation and
functions of the H3-receptor, Agents Actions 30 (1990) 13–23.
[46] M. Kathmann, E. Schlicker, M. Detzner, H. Timmerman,
Nordimaprit, homodimaprit, clobenpropit and imetit: affinities
for H3 binding sites and potencies in a functional H3-receptor
model, Naunyn-Schmiedeberg’s Arch. Pharmacol. 348 (1993)
498–503.
[47] M. Kathmann, E. Schlicker, M. Go¨thert, Intermediate affinity
and potency of clozapine and low affinity of other neuroleptics
and of antidepressants at H3-receptors, Psychopharmacology 116
(1994) 464–468.
[48] A. Alves-Rodriguez, F.P. Jansen, R. Leurs, G.D. Prell, H.
Timmerman, Interaction of clozapine with the histamine H3-re-
ceptor in the rat brain, Br. J. Pharmacol. 114 (1995) 1523–1524.
[49] C.R. Ganellin, F. Lurquin, A. Piripitsi, J.-M. Arrang, M. Gar-
barg, X. Ligneau, W. Schunack, J.-C. Schwartz, Synthesis of
potent non-imidazole histamine H3-receptor antagonists, Arch.
Pharm. Med. Chem. 331 (1998) 395–404.
[50] F. Bordi, M. Mor, G. Morini, P.V. Plazzi, C. Silva, T. Vitali,
QSAR study on H3-receptor affinity of benzothiazole derivatives
of thioperamide, Farmaco 49 (1994) 153–166.
[30] R. Lipp, H. Stark, W. Schunack, Pharmacochemistry of H3-re-
ceptors, in: J.-C. Schwartz, H.L Haas (Eds.), The Histamine
Receptor, Ser. Receptor Biochemistry and Methodology, vol. 16,
Wiley-Liss, New York/Basel, 1992, pp. 57–72.
[31] R. Leurs, R.C. Vollinga, H. Timmerman, The medicinal chem-
istry and therapeutic potentials of ligands of the histamine
H3-receptor, in: Progress in Drug Research, vol. 45, Birkha¨user,
Basel, 1995, pp. 107–165.
[32] R. Leurs, H. Timmerman, The histamine H3-receptor: A target
for developing new drugs, in: Progress in Drug Research, vol. 39,
Birkha¨user, Basel, 1992, pp. 127–165.
[51] R. Iemura, T. Kawashima, T. Fukuda, K. Ito, G. Tsukamoto,
2-(4-Substituted-1-piperazinyl)benzimidazoles as H1 antihis-
taminic agents, J. Med. Chem. 29 (1986) 1178–1183.
[33] R. Leurs, P. Blandina, C. Tedford, H. Timmerman, Therapeutic